BioCardia, Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 51.51. In total, the insiders bought 2 458 796 and sold 385 660 BCDA shares in the last 100 trades.

Insider Power

(Last 100 transactions)
51.51
Buy 2 458 796 Shares
Sell 385 660 Shares

Historical Insider Trades

Date Type Action Person Amount
Jan 19, 2024 Common Stock Sell Frost Phillip Md Et Al 129 802
Oct 18, 2023 Stock Option (right to buy) Buy Blank Andrew Scott 12 434
Oct 18, 2023 Stock Option (right to buy) Buy Krasno Richard M 12 434
Oct 18, 2023 Stock Option (right to buy) Buy Moyes Jay M 12 434
Oct 18, 2023 Stock Option (right to buy) Buy Allen Jim L. 12 434
Oct 18, 2023 Stock Option (right to buy) Buy Stertzer Simon H 12 434
Oct 18, 2023 Stock Option (right to buy) Buy Facteau Bill 31 085
Oct 18, 2023 Stock Option (right to buy) Buy Facteau Bill 12 434
Oct 18, 2023 Buy Facteau Bill 0
Aug 17, 2023 Common Stock Buy Altman Peter 4 000
Aug 17, 2023 Common Stock Buy Altman Peter 4 000
Aug 14, 2023 Common Stock Buy Altman Peter 4 500
Aug 14, 2023 Common Stock Buy Altman Peter 4 500
Jun 23, 2023 Common Stock Buy Altman Peter 6 421
Jun 23, 2023 Common Stock Buy Mcclung David 4 280
Jun 23, 2023 Common Stock Buy Allen Jim L. 64 212
Jun 23, 2023 Common Stock Buy Blank Andrew Scott 64 212
Jun 23, 2023 Common Stock Buy Stertzer Simon H 64 212
May 31, 2023 Common Stock Sell Gillis Edward M 15 512
May 31, 2023 Common Stock Sell Mcclung David 20 676
May 31, 2023 Common Stock Sell Altman Peter 36 821
May 26, 2023 Common Stock Buy Altman Peter 6 200
May 18, 2023 Stock Option (right to buy) Buy Gillis Edward M 43 803
May 18, 2023 Common Stock Buy Gillis Edward M 40 490
May 18, 2023 Common Stock Buy Mcclung David 61 389
Click to get the best stock tips daily for free!

About BioCardia, Inc.

BioCardia. BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture... BCDA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT